COMPARE · Reviewed July 29, 2026
ADUS vs CI
Verdict: Side-by-side breakdown using the Bull Rankings model. ADUS scored 75.1, CI scored 73.2 — ADUS leads.
Compare another set
ADUS
Addus HomeCare Corporation
75.1
$119.13 · $2.2B
fundamentals as of
Score gap
1.9
ADUS leads
CI
The Cigna Group
73.2
$296.47 · $78.4B
fundamentals as of
The model, pillar by pillar (0–100 each)
ADUS
stronger →← stronger
CI
57
Qualityreturns · margins · balance sheet
59
96
Growthrevenue & earnings expansion
85
77
Valuevaluation vs sector peers
78
ADUS and CI split the three pillars evenly.
Fundamentals, head-to-head
ADUS
CI
$137mC
FCF
$7.7bB+
+19.6%B+
Rev
+11.3%B
0.12B+
D/E
0.73C+
22.0xB+
P/E
12.6xA
1.11B+
PEG
0.87B+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADUS
CI
9% below
Price vs fair valuelower is cheaper
41% below
~3%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-6%/yr
+4%
1-yr DCF upside
+54%
+10%
5-yr DCF upside
+68%
+18%
10-yr DCF upside
+92%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ADUS
No notable signals flagged.
CI
Why this score
- Raising its dividend
The companies
ADUSAddus HomeCare Corporation
Why now
Medical Care Facilities · market cap $2.2b. 4% off the 52-week high of $124.44. Revenue growing +20%, comfortably above the S&P median. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $133.00 (implying +12% upside).
Moat
FCF converts 138% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
CIThe Cigna Group
Why now
Healthcare Plans · market cap $78.4b. 6% off the 52-week high of $315.47. Revenue growing +11%, comfortably above the S&P median. PEG 0.87 — paying under fair value for the growth rate. 24 sell-side analysts publish a mean 1-yr target of $340.92 (implying +15% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 122% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $78.4b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Net margin 2.3% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.